Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 856 to 870 of 1335 results for primary care

  1. The STAK tool for preventing and treating knee stiffness (MIB252)

    NICE has developed a medtech innovation briefing (MIB) on the STAK tool for preventing and treating knee stiffness .

    Medtech innovation briefing
    Published
    9 February 2021

  2. Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)

    Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults who have had previous treatment with a docetaxel-containing regimen.

    Technology appraisal guidance
    Last updated
    27 July 2016
    View recommendations

    Sections for TA259

  3. How does the duration and frequency of brief advice influence its effectiveness and cost effectiveness? For example, do 'micro interventions' of less than 1–2 minutes have an impact on physical activity?

    Comes from guidance Physical activity: brief advice for adults in primary care Number PH44 Date issued May 2013 Other details

    Research recommendation
    Published
    9 June 2015

  4. How can brief advice be tailored to have the greatest impact on specific groups? For example, can it be tailored to meet the needs of people of a particular gender, socioeconomic status or with a particular disability?

    Comes from guidance Physical activity: brief advice for adults in primary care Number PH44 Date issued May 2013 Other details

    Research recommendation
    Published
    9 June 2015

  5. Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

    Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

    Evidence summary
    Published
    24 May 2016

  6. Human growth hormone (somatropin) in adults with growth hormone deficiency (TA64)

    Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth hormone deficiency in adults.

    Technology appraisal guidance
    Published
    27 August 2003
    View recommendations

    Sections for TA64

  7. Everolimus for advanced renal cell carcinoma after previous treatment (TA432)

    Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.

    Technology appraisal guidance
    Published
    22 February 2017
    View recommendations

    Sections for TA432

  8. Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (TA825)

    Evidence-based recommendations on avacopan (Tavneos) for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis in adults.

    Technology appraisal guidance
    Published
    21 September 2022
    View recommendations

    Sections for TA825

  9. Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)

    Evidence-based recommendations on tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease in adults.

    Technology appraisal guidance
    Published
    28 October 2015
    View recommendations

    Sections for TA358

  10. Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (TA649)

    Evidence-based recommendations on polatuzumab vedotin (Polivy) with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have a haematopoietic stem cell transplant.

    Technology appraisal guidance
    Published
    23 September 2020
    View recommendations

    Sections for TA649

  11. What infrastructures and systems help increase the number of assessments of physical activity undertaken and the delivery of brief advice? (Examples studied could include integration of brief advice into long-term disease management strategies, or the use of incentive strategies.)

    Comes from guidance Physical activity: brief advice for adults in primary care Number PH44 Date issued May 2013 Other details

    Research recommendation
    Published
    9 June 2015

  12. Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)

    Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia in remission with minimal residual disease activity in adults.

    Technology appraisal guidance
    Published
    24 July 2019
    View recommendations

    Sections for TA589

  13. The AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation (MIB18)

    NICE has developed a Medtech Innovation Briefing (MIB) on the AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation

    Medtech innovation briefing
    Published
    12 February 2015

  14. Guide to the methods of technology appraisal 2013 (PMG9)

    Guide to the methods of technology appraisal 2013

  15. Bulevirtide for treating chronic hepatitis D (TA896)

    Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.

    Technology appraisal guidance
    Published
    7 June 2023
    View recommendations

    Sections for TA896